February 13, 2006 -- Genentech will temporarily halt enrollment in a colorectal cancer trial following a small number of unexplained deaths; late on Friday, Genentech and Biogen Idec received word that the FDA approved Rituxan as a first-line treatment for non-Hodgkin’s lymphoma; Novacea filed to raise $75 million in its IPO; Xenogen agreed to be bought by Caliper Life Sciences for $80 million in stock and warrants; Cerus in-licensed the remaining commercial rights to the Intercept Blood System from Baxter; and Amgen in-licensed the worldwide rights to a drug family from collaborator Biovitrum. The Centient Biotech 200™ was 30 points lower at 3845.60, a .77% loss. More details...
